Gene therapy for haemophagocytic lymphohistiocytosis

Current Gene Therapy

Volumn 14, Issue 6, 2014, Pages 437-446

  Booth, Claire ^a,b   Carmo, Marlene ^a   Gaspar, H Bobby ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Gene therapy; Haematopoietic stem cell transplantation; Haemophagocytic lymphohistiocytosis; Lentiviral vector

Indexed keywords

MURINAE;

MEMBRANE PROTEIN;

ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MOUSE; MULTIMODALITY CANCER THERAPY; THERAPEUTIC USE;

ANIMALS; COMBINED MODALITY THERAPY; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MEMBRANE GLYCOPROTEINS; MICE;

EID: 84924810410     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140918112113     Document Type: Article

References (82)

1. [1] Janka GE: Hemophagocytic syndromes. Blood Rev 2007; 21(5): 245-53.
2. [2] Horne A, Trottestam H, Arico M, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 2008; 140(3): 327-35.
3. [3] Morrell DS, Pepping MA, Scott JP, Esterly NB, Drolet BA. Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch Dermatol 2002; 138(9): 1208-12.
4. [4] Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated targetcell death and immune homeostasis. Nat Rev Immunol 2006; 6(12): 940-52.
5. [5] Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (hlh): CD8+ t cells and interferon gamma are essential for the disorder. Blood 2004; 104(3): 735-43.
6. [6] Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78(11): 2918-22.
7. [7] Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (hps). Autoimmun Rev 2004; 3(2): 69-75.
8. [8] Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165(3): 538-46.
9. [9] Ohadi M, Lalloz MR, Sham P, et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet 1999; 64(1): 165-71.
10. [10] Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: Advances in the genetic basis, diagnosis and management. Clin Exp Immunol 2011; 163(3): 271-83.
11. [11] Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286(5446): 1957-9.
12. [12] Goransdotter EK, Fadeel B, Nilsson-Ardnor S, et al. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet 2001; 68(3): 590-7.
13. [13] Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118(15): 4041-52.
14. [14] An O, Gursoy A, Gurgey A, Keskin O. Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (fhl2) patients. Protein Sci 2013; 22(6): 823-39.
15. [15] Feldmann J, Le Deist F, Ouachee-Chardin M, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol 2002; 117(4): 965-72.
16. [16] Horne A, Ramme KG, Rudd E, et al. Characterization of prf1, stx11 and unc13d genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol 2008; 143(1): 75-83.
17. [17] Trizzino A, zur Stadt U, Ueda I, et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet 2008; 45(1): 15-21.
18. [18] Rudd E, Bryceson YT, Zheng C, et al. Spectrum, and clinical and functional implications of unc13d mutations in familial haemophagocytic lymphohistiocytosis. J Med Genet 2008; 45(3): 134-41.
19. [19] Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (fhl3). Cell 2003; 115(4): 461-73.
20. [20] Menager MM, Menasche G, Romao M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hmunc13-4. Nat Immunol 2007; 8(3): 257-67.
21. [21] zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (fhl) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 2005; 14(6): 827-34.
22. [22] Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with munc13-4 polymorphisms. Arthritis Rheum 2008; 58(9): 2892-6.
23. [23] Zhang S, Ma D, Wang X, et al. Syntaxin-11 is expressed in primary human monocytes/macrophages and acts as a negative regulator of macrophage engulfment of apoptotic cells and iggopsonized target cells. Br J Haematol 2008; 142(3): 469-79.
24. [24] Arneson LN, Brickshawana A, Segovis CM, Schoon RA, Dick CJ, Leibson PJ. Cutting edge: Syntaxin 11 regulates lymphocytemediated secretion and cytotoxicity. J Immunol 2007; 179(6): 3397-401.
25. [25] Bryceson YT, Rudd E, Zheng C, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (fhl4) patients. Blood 2007; 110(6): 1906-15.
26. [26] Cote M, Menager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient nk cells. J Clin Invest 2009; 119(12): 3765-73.
27. [27] zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (fhl-5) is caused by mutations in munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet 2009; 85(4): 482-92.
28. [28] Nichols KE, Harkin DP, Levitz S, et al: Inactivating mutations in an sh2 domain-encoding gene in x-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 1998; 95(23): 13765-70.
29. [29] Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to ebv infection in x-linked lymphoproliferative disease results from mutations in an sh2-domain encoding gene. Nat Genet 1998; 20(2): 129-35.
30. [30] Sayos J, Wu C, Morra M, et al. The x-linked lymphoproliferativedisease gene product sap regulates signals induced through the coreceptor slam. Nature 1998; 395(6701): 462-9.
31. [31] Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease. 2b4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill epstein-barr virus-infected cells. J Exp Med 2000; 192(3): 337-46.
32. [32] Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for sap in 2b4-mediated activation of human natural killer cells as revealed by the x-linked lymphoproliferative syndrome. J Immunol 2000; 165(6): 2932-6.
33. [33] Dupre L, Andolfi G, Tangye SG, et al. Sap controls the cytolytic activity of cd8+ t cells against ebv-infected cells. Blood 2005; 105(11): 4383-9.
34. [34] Pasquier B, Yin L, Fondaneche MC, et al. Defective nkt cell development in mice and humans lacking the adapter sap, the xlinked lymphoproliferative syndrome gene product. J Exp Med 2005; 201(5): 695-701.
35. [35] Nunez-Cruz S, Yeo WC, Rothman J, et al. Differential requirement for the sap-fyn interaction during NK T cell development and function. J Immunol 2008; 181(4): 2311-20.
36. [36] Veillette A, Zhang S, Shi X, Dong Z, Davidson D, Zhong MC. Sap expression in T cells, not in B cells, is required for humoral immunity. Proc Natl Acad Sci U S A 2008; 105(4): 1273-8.
37. [37] Crotty S, Kersh EN, Cannons J, Schwartzberg PL, Ahmed R. Sap is required for generating long-term humoral immunity. Nature 2003; 421(6920): 282-7.
38. [38] Qi H, Cannons JL, Klauschen F, Schwartzberg PL, Germain RN. Sap-controlled t-b cell interactions underlie germinal centre formation. Nature 2008; 455(7214): 764-9.
39. [39] Nagy N, Matskova L, Hellman U, Klein G, Klein E. The apoptosis modulating role of sap (slam associated protein) contributes to the symptomatology of the x linked lymphoproliferative disease. Cell Cycle 2009; 8(19): 3086-90.
40. [40] Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to sap/sh2d1a deficiency: A multicenter study on the manifestations, management and outcome of the disease. Blood 2011; 117(1): 53-62.
41. [41] Rigaud S, Fondaneche MC, Lambert N, et al. Xiap deficiency in humans causes an x-linked lymphoproliferative syndrome. Nature 2006; 444(7115): 110-4.
42. [42] Pachlopnik SJ, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with x-linked lymphoproliferative syndrome type 1 (xlp-1/sap deficiency) versus type 2 (xlp-2/xiap deficiency). Blood 2011; 117(5): 1522-9.
43. [43] Speckmann C, Lehmberg K, Albert MH, et al. X-linked inhibitor of apoptosis (xiap) deficiency: The spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013; 149(1): 133-41.
44. [44] Huck K, Feyen O, Niehues T, et al. Girls homozygous for an il-2-inducible t cell kinase mutation that leads to protein deficiency develop fatal ebv-associated lymphoproliferation. J Clin Invest 2009; 119(5): 1350-8.
45. [45] van Montfrans JM, Hoepelman AI, Otto S, et al. Cd27 deficiency is associated with combined immunodeficiency and persistent symptomatic ebv viremia. J Allergy Clin Immunol 2012; 129(3): 787-93.
46. [46] Salzer E, Daschkey S, Choo S, et al. Combined immunodeficiency with life-threatening ebv-associated lymphoproliferative disorder in patients lacking functional cd27. Haematologica 2013; 98(3): 473-8.
47. [47] Li FY, Lenardo MJ, Chaigne-Delalande B. Loss of magt1 abrogates the mg2+ flux required for t cell signaling and leads to a novel human primary immunodeficiency. Magnes Res 2011; 24(3): S109-14.
48. [48] Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: Advances in pathophysiology, diagnosis, and treatment. J Pediatr 2013; 163(5): 1253-9.
49. [49] Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012; 119(12): 2754-63.
50. [50] Jessen B, Maul-Pavicic A, Ufheil H, et al. Subtle differences in ctl cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with chediak-higashi syndrome. Blood 2011; 118(17): 4620-9.
51. [51] Menasche G, Feldmann J, Fischer A, de Saint Basile G. Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev 2005; 203: 165-79.
52. [52] Stinchcombe JC, Griffiths GM: Secretory mechanisms in cellmediated cytotoxicity. Annu Rev Cell Dev Biol 2007; 23: 495-517.
53. [53] Jessen B, Bode SF, Ammann S, et al. The risk of hemophagocytic lymphohistiocytosis in hermansky-pudlak syndrome type 2. Blood 2013; 121(15): 2943-51.
54. [54] Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 50(6): 1227-35.
55. [55] Wheeler RD, Cale CM, Cetica V, Arico M, Gilmour KC. A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol 2010; 150(6): 727-30.
56. [56] Henter JI, Elinder G, Soder O, Ost A. Incidence in sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991; 80(4): 428-35.
57. [57] Trottestam H, Horne A, Arico M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the hlh-94 treatment protocol. Blood 2011; 118(17): 4577-84.
58. [58] Henter JI, Horne A, Arico M, et al. Hlh-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48(2): 124-31.
59. [59] Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients. Pediatrics 2007; 120(3): e622-8.
60. [60] Marsh RA, Vaughn G, Kim MO, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010; 116(26): 5824-31.
61. [61] Marsh RA, Rao K, Satwani P, et al. Allogeneic hematopoietic cell transplantation for xiap deficiency: An international survey reveals poor outcomes. Blood 2013; 121(6): 877-83.
62. [62] Terrell CE, Jordan MB. Mixed hematopoietic or t-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood 2013; 122(15): 2618-21.
63. [63] Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341(6148): 1233158.
64. [64] Pipkin ME, Rao A, Lichtenheld MG. The transcriptional control of the perforin locus. Immunol Rev 2010; 235(1): 55-72.
65. [65] Rivat C, Booth C, Alonso-Ferrero M, et al. Sap gene transfer restores cellular and humoral immune function in a murine model of x-linked lymphoproliferative disease. Blood 2013; 121(7): 1073-6.
66. [66] Ouachee-Chardin M, Elie C, de Saint Basile G, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: A single-center report of 48 patients. Pediatrics 2006; 117(4): e743-50.
67. [67] Horne A, Janka G, Maarten Egeler R, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 2005; 129(5): 622-30.
68. [68] Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: Long-term results of the first clinical gene therapy trial. Blood 2003; 101(7): 2563-9.
69. [69] Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ada-scid: Initial trial results after 4 years. Science 1995; 270(5235): 475-80.
70. [70] Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for adaimmunodeficient patients. Science 1995; 270(5235): 470-5.
71. [71] Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of cd4zeta genemodified autologous cd4(+) and cd8(+) t cells in human immunodeficiency virus-infected subjects. Blood 2000; 96(3): 785-93.
72. [72] Deeks SG, Wagner B, Anton PA, et al. A phase ii randomized study of hiv-specific t-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5(6): 788-97.
73. [73] Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicidegene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the tk007 trial): A non-randomised phase i-ii study. Lancet Oncol 2009; 10(5): 489-500.
74. [74] Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor t cells. Sci Transl Med 2012; 4(132): 132153.
75. [75] Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26(32): 5233-9.
76. [76] Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3(95): 95-73.
77. [77] Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified t cells in chronic lymphoid leukemia. N Engl J Med 2011; 365(8): 725-33.
78. [78] Tebas P, Stein D, Tang WW, et al. Gene editing of ccr5 in autologous cd4 t cells of persons infected with hiv. N Engl J Med 2014; 370(10): 901-10.
79. [79] Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9(9): 510-9.
80. [80] Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virusspecific t cells that target cmv, adenovirus, and ebv can be expanded from naive t-cell populations in cord blood and will target a range of viral epitopes. Blood 2009; 114(9): 1958-67.
81. [81] Sellar RS, Peggs KS. The role of virus-specific adoptive t-cell therapy in hematopoietic transplantation. Cytotherapy 2012; 14(4): 391-400.
82. [82] Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child 2011; 96(7): 688-93.